Are BRCA1 and BRCA2 gene mutation patients underscreened for pancreatic adenocarcinoma?
Alexandra M RochJustine SchneiderRosalie A CarrWilliam P LancasterMichael G HouseNicholas J ZyromskiAttila NakeebC Max SchmidtEugene P CeppaPublished in: Journal of surgical oncology (2019)
In this series, 4% and 17% of BRCA2 patients developed PDAC and IPMN, respectively. Eight percent of BRCA1 patients developed IPMN. Under current recommended screening, 60% of BRCA1/2 patients had incompletely pancreatic assessment. With no influence of family history, this study suggests all BRCA1/2 patients should undergo a high-risk screening protocol that will identify a higher rate of precancerous pancreatic neoplasms amenable to curative resection.